<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04804111</url>
  </required_header>
  <id_info>
    <org_study_id>JWP-URC-203</org_study_id>
    <nct_id>NCT04804111</nct_id>
  </id_info>
  <brief_title>Study of of URC102 to Assess the Efficacy and Safety in Gout Patients</brief_title>
  <acronym>URC102</acronym>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-finding Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of URC102 in Patient With Gout</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JW Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JW Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the safety and efficacy (dose response and optimal dose according to the serum&#xD;
      uric acid response rate) of URC102 when orally-administered to patients with gout and&#xD;
      gout-related hyperuricemia in comparison with placebo.&#xD;
&#xD;
      Therapeutic dose-finding study, Placebo-controlled, randomized, double-blind, multicenter,&#xD;
      phase 2 clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Placebo-controlled, randomized, double-blind, multicenter, phase 2 clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2019</start_date>
  <completion_date type="Actual">November 29, 2020</completion_date>
  <primary_completion_date type="Actual">September 4, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum uric acid response rate (&lt; 6.0 mg/dL) at week 4 after the IP administration.</measure>
    <time_frame>Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid response rate (&lt; 5.0 mg/dL) at week 4 after the IP administration.</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Uric Acid from Baseline to week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Uric Acid at week 4 from Baseline</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence rate of gout attack from baseline to week 4</measure>
    <time_frame>week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid response rate(&lt; 6.0 mg/dL) at week 8 and week 12 after the IP administration</measure>
    <time_frame>Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum uric acid response rate(&lt; 5.0 mg/dL) at week 8 and week 12 after the IP administration</measure>
    <time_frame>Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Serum Uric Acid from Baseline to week 8 and week 12</measure>
    <time_frame>Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Uric Acid at week 8 and 12 from Baseline</measure>
    <time_frame>Week 8, Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence rate of gout attack from baseline to week 8 and 12</measure>
    <time_frame>Week 8, Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Gout</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>maintain the initial dose, without increasing the dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URC102 3mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administer 3 mg of URC102 for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URC102 6mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 11 Weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>URC102 9mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administer 3 mg of URC102 for 1 week and 6 mg of URC102 for 1 Weeks, maintain 9 mg of URC102 dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat 80 mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>maintain the initial dose, without increasing the dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arm 0</intervention_name>
    <description>placebo group</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arm 1</intervention_name>
    <description>3 mg of the URC102 group</description>
    <arm_group_label>URC102 3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arm 2</intervention_name>
    <description>6 mg of the URC102 group</description>
    <arm_group_label>URC102 6mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arm 3</intervention_name>
    <description>9 mg of the URC102 group</description>
    <arm_group_label>URC102 9mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arm 4</intervention_name>
    <description>Febuxostat 80 mg</description>
    <arm_group_label>Febuxostat 80 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Screening Inclusion Criteria The subjects must meet all the following criteria to be&#xD;
             eligible for articipation in this study.&#xD;
&#xD;
               1. Subjects who are aged ≥19 and &lt;70 years at the time of providing written informed&#xD;
                  consent&#xD;
&#xD;
               2. Subjects who are diagnosed with gout according to American College of&#xD;
                  Rheumatology (1977) criteria for the classification of acute arthritis of primary&#xD;
                  gout.&#xD;
&#xD;
               3. Subjects who have the ability and willingness to actively conduct TLC recommended&#xD;
                  in this study&#xD;
&#xD;
               4. Subjects who provided written informed consent to voluntarily participate in the&#xD;
                  study&#xD;
&#xD;
          -  Randomization Inclusion Criterion. Subjects who meet the screening inclusion criteria&#xD;
             will be randomly assigned to the following criteria.&#xD;
&#xD;
               1. sUA ≥ 7.0 mg/dL at Visit 2&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
               1. Subjects who have medical history or comorbidity as follow; (1) Active malignancy&#xD;
                  or history of malignancy within the past 5 years at the time of screening (2)&#xD;
                  Urolithiasis (3) Clinically important allergic disease (anaphylactic shock, etc.)&#xD;
                  (4) Lesch-Nyhan syndrome (5) Hereditary problems such as galactose intolerance,&#xD;
                  Lapp lactase deficiency or glucose-galactose malabsorption (6) Ischemic heart&#xD;
                  diseases or congestive heart failure (7) Organ transplantation (recipient or&#xD;
                  scheduled to receipt)&#xD;
&#xD;
               2. Subjects who have comorbidity or abnormality of lab results as follows; (1)&#xD;
                  Uncontrolled diabetes mellitus with drug therapy&#xD;
&#xD;
                    -  HbA1c ≥ 9% or&#xD;
&#xD;
                    -  Fasting plasma glucose (FPG) ≥160 mg/dL (2) Uncontrolled hypertension with&#xD;
                       treatment&#xD;
&#xD;
                    -  Systolic blood pressure (SBP) ≥180 mmHg or&#xD;
&#xD;
                    -  Diastolic blood pressure (DBP) ≥ 110 mmHg (3) Uncontrolled dyslipidemia with&#xD;
                       treatment&#xD;
&#xD;
                    -  Total cholesterol ≥ 250 mg/dL (at least 8 hours of fasting) (4) Aspartate&#xD;
                       aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 2 X upper limit&#xD;
                       of normal (ULN) or Total bilirubin ≥ 1.5 X ULN (5) eGFR* &lt; 60 mL/min/1.73m2&#xD;
                       * eGFR (MDRD equation) GFR(ml/min/1.73m2) = 186 × (SCr)-1.154 × (age)-0.203&#xD;
                       × (0.742 if female) × (1.210 if African American) (6) Uncontrolled thyroid&#xD;
                       function with treatment (thyroid-stimulating hormone (TSH) ≥ 1.5 X UNL&#xD;
&#xD;
               3. Subjects who are judged by the investigator to have a clinical cardiovascular&#xD;
                  disease that may affect the study based on the 12-lead ECG obtained at screening&#xD;
                  or those suspected to be at such risk&#xD;
&#xD;
               4. Patients who have received or plan to receive any XOI or uricosuric agents within&#xD;
                  3 weeks prior to study treatment&#xD;
&#xD;
               5. Patients who have received or plan to receive diuretics or any medication action&#xD;
                  on human Uric Acid Transporter 1(hURAT1) such as indomethacin, pyrazinamide,&#xD;
                  fenofibrate, atorvastatin, amlodipine, losartan, captopril, enalapril,&#xD;
                  salicylates etc. within 2 weeks prior to study treatment However, those who have&#xD;
                  been on stable doses as below are allowed to participate in the study, if the&#xD;
                  administration method and dosage remain the same during the study period (1)&#xD;
                  Diuretics (thiazide only or thiazide-based combination, etc.) and&#xD;
                  antihypertensive agents (losartan etc.) used for the treatment of hypertension&#xD;
                  (2) Fenofibrate or lipid lowering drugs (atorvastatin) used for hyperlipidemia&#xD;
                  (3) Salicylates (aspirin)&#xD;
&#xD;
               6. Patients who have been administered or plan to administer Mercaptopurine,&#xD;
                  Azathioprine, Theophyline within 1 week or within more than 5 times of its&#xD;
                  half-life prior to the Visit 1&#xD;
&#xD;
               7. HIV Ag/Ab, HBs Ag or HCV Ab positive at screening&#xD;
&#xD;
               8. Subjects who have known hypersensitivity or allergy to IPs (URC102 or febuxostat)&#xD;
                  or any components in their formulations&#xD;
&#xD;
               9. Subjects who have childbearing or nursing&#xD;
&#xD;
              10. Subjects who agree to use methods of birth control* during the study period and&#xD;
                  for up to 7 days after the final administration of the IP&#xD;
&#xD;
                  * Methods of birth control: ① intrauterine device or birth control implant, ②&#xD;
                  dual protection (condom with spermicide and contraceptive diaphragm or&#xD;
                  contraceptive sponge or cervical cap ③ surgical sterilization (vasectomy or tubal&#xD;
                  ligation or etc.)&#xD;
&#xD;
              11. Subjects who have been administered any other IP or investigational device by&#xD;
                  participating in other studieswithin 4 weeks or within more than 5 times of its&#xD;
                  halflife prior to the Visit 1&#xD;
&#xD;
              12. Subjects who have a history of drug or alcohol abuse within 5 years prior to the&#xD;
                  Visit 1&#xD;
&#xD;
              13. Subjects who have any other reason that may affect the study or those who are&#xD;
                  judged by the investigator to be ineligible for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>JW Pharmaceutical</name>
      <address>
        <city>Seoul</city>
        <zip>06725</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chung-Ang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

